- Home
- HCA vs VRTX Comparison
HCA vs VRTX Comparison
Compare HCA & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | VRTX |
|---|---|---|
| Founded | 1968 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5B | 115.7B |
| IPO Year | 2009 | 2006 |
Fundamental Metrics
Financial Performance| Metric | HCA | VRTX |
|---|---|---|
| Price | $481.57 | $432.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 29 |
| Target Price | $528.00 | ★ $539.69 |
| AVG Volume (30 Days) | 822.9K | ★ 1.2M |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | 28.77 | ★ 836.54 |
| EPS | ★ 28.33 | 15.32 |
| Revenue | ★ $75,600,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $5.07 | $10.81 |
| Revenue Next Year | $4.90 | $10.41 |
| P/E Ratio | ★ $17.29 | $28.88 |
| Revenue Growth | 7.08 | ★ 46.20 |
| 52 Week Low | $314.43 | $362.50 |
| 52 Week High | $556.52 | $510.77 |
Technical Indicators
Market Signals| Indicator | HCA | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 42.19 |
| Support Level | $461.11 | $429.47 |
| Resistance Level | $519.90 | $442.22 |
| Average True Range (ATR) | 12.77 | 11.35 |
| MACD | 1.49 | 0.45 |
| Stochastic Oscillator | 45.43 | 37.47 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.